Clinique Pasteur — Clinical Trial Site

51 Registered trials

23 Currently recruiting

Organisation

Clinique Pasteur

Location

Toulouse Cedex 3, France

Identifier

ORG-100046819

Address

45 Avenue De Lombez, Cs 27617, 31076, France

Departments

Anaesthesia and Intensive Care
ANESTHESIE REANIMATION
Anesthésie-Réanimation
Cardiologie
CARDIOLOGY
Cardiology and cardio-thoracic and vascular surgery
Cardiology/EP
Centre hépato-biliaire Service de gastro-enterologie
Chirurgie Oncologique Gynécologique
Departement de Cardiologie
Département de radiothérapie
Gastro-enterology, Endoscopy and Hepatic Diseases
Gastro-hepato-entérologie
Gastroentérologie
Gastroenterology
Groupe CardioVasculaire Interventionnel
Interventional Cardiovascular Group
Medical Oncology
ONCOLOGIE
Oncology
Oncology - radiotherapy
Pneumology
Radiotherapy
Service de Gastro-Enterologie
Service gastro entérologie, endoscopie et maladies du foie
Service Oncologie Hématologie
Unity of Oncology and Hematology (ONCOSUD)
Urologie
Urology

Clinical trials at this site (51)

Search interface

Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi… Recruiting

2023-508154-25-00 Crohn's disease 6 2024-05-27
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting

2023-505251-43-00 Primary Biliary Cholangitis 5 2024-02-28
Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n… Recruiting

2023-504637-42-01 aortic valve stenosis 6 2023-12-21
PROPHYLOXITIN-Intermittent cefoxitin administration versus loading bolus followed by continuous infusion for the prevention of surgical site… Recruiting

2024-515146-16-00 Colorectal surgery 5 2023-05-15
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Multicentre, randomized, controlled, open-label, multi-centre medicoeconomic study evaluating the efficacy of adding zoledronic acid or deno… Recruiting

2024-513248-27-00 Patients, men or women over 18 old, with inoperable ver 5 2020-07-20
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat… Ended

2024-515433-15-02 acute coronary syndrome 6 2025-01-29
A Study of Elafibranor in Adults with Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid Ended

2024-510695-20-00 Primary Biliary Cholangitis (PBC) 5 2024-10-15
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended

2023-509494-23-00 Adult patients with intermediate unfavorable risk prost 4 2023-02-20
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
The TARGET BP I Ended

2024-512525-83-00 Hypertension 5 2020-01-07
A clinical study evaluating the benefits of apalutamide, a novel drug targeting prostate cancer growth, in combination with radiotherapy and… Ended

2024-514829-36-00 High-risk biochemically-relapsed prostate adenocarcinom 5 2019-12-02
Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II … Ended

2024-513207-13-00 oligometastatic hormone sensitive prostate cancer 4 2019-03-21
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended

2024-516198-61-00 Patients with high risk of relapse, ER+ and HER2- prima 5 2013-06-05
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco… Ended

2024-516996-34-00 oestrogen-receptor (ER)-positive HER2-negative breast c 5 2012-04-12
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients Ended

2024-515171-35-00 Prostatic adenocarnicoma with high risk of recurrence 5 2011-07-06
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase… Halted

2024-513576-18-00 Cervical Cancer 5 2020-07-17
Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien… Ended

2022-502584-38-00 Locally advanced squamous cell carcinoma of the head an 5 2023-12-12
ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended

2022-501802-36-00 Prevention of cardiac surgery associated acute kidney i 5 2023-06-16